Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180145 | 0.85 | CTSK (0.38) | CTSK | |
| SCHEMBL6894951 | 0.83 | CTSK (0.38) | CTSK | |
| SCHEMBL3815702 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL6894010 | 0.82 | MAPT (0.33) | — | |
| SCHEMBL6899777 | 0.81 | TSHR (0.42) | CTSK | |
| Bicarbonate SCHEMBL3240516 | 0.80 | CTSK (0.36) | CTSK | |
| SCHEMBL6583616 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL6895950 | 0.79 | CTSK (0.39) | CTSK | |
| SCHEMBL19018871 | 0.79 | MAPT (0.34) | CTSK | |
| SCHEMBL20260454 | 0.78 | ALDH1A1 (0.32) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040176350-A1 | Carbapenem compound | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1398314-A1 | CARBAPENEM COMPOUND | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-0482657-A2 | Cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | CTSK 3012/4885 |
| US-20040176350-A1 | Carbapenem compound | ALPI, SI, OXA1L | CTSK 2122/4885 |
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | CTSK 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.